Forte Biosciences

FBRX

Market cap $1.16B

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.

Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vitiligo, suggesting platform potential beyond a single indication. FB102's mechanism targets CD122, modulating key immune pathways, with placebo-controlled data showing 21.7% F-VASI benefit in vitiligo and histologic protection in celiac disease. FBRX holds a pro forma cash position of ~$220M post-financing, providing 11–12 quarters of runway to advance Phase II/III trials across multiple autoimmune indications.

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript

Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational therapy for vitiligo, showing statistically significant improvements in disease severity compared with placebo. Vitiligo is a chronic autoimmune disorder where the immune system destroys melanocytes, the pigment-producing cells responsible for skin color, resulting in distinct white patches on the skin, hair, or mucous membranes.

Forte Biosciences Inc. (NASDAQ:FBRX) on Thursday reported positive topline results from its Phase 1b trial evaluating FB102 in patients with vitiligo, a chronic autoimmune disorder where the immune system attacks melanocytes (pigment-producing cells).

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value = 0.020) Response to FB102 was observed early, with statistically significant improvements observed by the day 64 visit (p=0.023).

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c.

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102's potential to address the high unmet need in celiac disease. The clinical development for FB102 continue.

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive markets, represent major catalysts for FBRX in 2024.